RT info:eu-repo/semantics/article
T1 “Pharmacogenetics of siponimod: A systematic review” by Díaz-Villamarín et al. – Information is power
A1 Zubiaur, Pablo
A1 Saiz Rodríguez, Miriam
A1 Abad‐Santos, Francisco
K1 Pharmacogenetics
K1 Siponimod
K1 Secondarily progressive multiple sclerosis (SPMS)
K1 Farmacogenómica
K1 Pharmacogenomics
K1 Esclerosis múltiple
K1 Multiple sclerosis
AB On August 12, 2022, Biomedicine and Pharmacotherpy published asystematic review on the pharmacogenetics of siponimod by Díaz-Villamarínet al. [1] We would like to acknowledge the work done by theauthors, as siponimod is a drug that may occupy a priority place in themanagement of secondarily progressive multiple sclerosis (SPMS) withactive disease evidenced by relapses or imaging features of inflammatoryactivity. Therefore, we believe that research aimed at clarifying theimpact of genetic variants on the effectiveness and safety of this drug isneeded; therefore, we applaud the authors’ efforts with this systematicreview.We consider that there are several inconsistencies in the therapeuticrecommendations contained in the siponimod drug label and in thoseissued by the two most relevant international associations in pharmacogenetics:the Clinical Pharmacogenetics Implementation Consortium(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG).
PB Elsevier
SN 0753-3322
YR 2023
FD 2023-01
LK https://hdl.handle.net/10259/11924
UL https://hdl.handle.net/10259/11924
LA eng
NO P. Zubiaur is financed by Universidad Autónoma de Madrid, Margarita Salas contract, grants for the requalification of the Spanish university system.
DS Repositorio Institucional de la Universidad de Burgos
RD 08-sep-2026